ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.
Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.
The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.
Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF), but only in those with moderate to severe forms of the disease.
Men who have sex with men (MSM) will be offered protection against the human papillomavirus (HPV) via a national vaccination programme in England due to be rolled out latest this year, the government has confirmed.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has expanded the approved uses of Tillotts Pharma’s Entocort to include the induction of remission in patients with active microscopic colitis (MC).
Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).